Add Yahoo as a preferred source to see more of our stories on Google. CXCL12 may help scientists mass-produce artificial red blood cells by triggering key steps in their development. (CREDIT: ...
Rather than triggering cell migration, CXCL12 triggers changes inside the erythroblast to prepare it to lose its nucleus. This includes cell reorganization, organizing its genetic material, and ...
Cancer specialists have long known that anemia, caused by a lack of healthy red blood cells, can arise when cancer metastasizes to the bone, but it’s been unclear why. A research team led by Princeton ...
This image shows an 'erythroblastic island,' a tiny factory where new red blood cells are made. The pink cells are developing red blood cells, which gather around a central blue-stained macrophage ...
Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart disease. However, current reprogramming strategies require excessive factors due to ...
Scientists have been working on the artificial production of blood for several decades. Now, researchers from the University of Konstanz and Queen Mary University of London have taken an important ...
Scientists have been working on the artificial production of blood for several decades. Now, researchers from the University of Konstanz and Queen Mary University of London have taken an important ...
Scientists from the University of Konstanz and Queen Mary University of London have identified a key molecular trigger that facilitates a crucial step in the formation of red blood cells. The finding ...
In a significant leap toward artificial blood, scientists at the University of Konstanz and Queen Mary University of London have uncovered how a single molecule, chemokine CXCL12, triggers a crucial ...
A breakthrough in the understanding of how mammals create red blood cells by Dr Julia Gutjahr, who began her research into the mechanisms of blood production in the lab of Professor Antal Rot in the ...
Luspatercept significantly improved hemoglobin levels in non-transfusion-dependent patients with lower-risk myelodysplastic syndromes, potentially delaying transfusion needs. The study showed a 47.6% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results